Ixekizumab
Brand name: Taltz Autoinjector
Rank #115 of 500 drugs by total cost
$149.8M
Total Cost
19,972
Total Claims
$149.8M
Total Cost
1,087
Prescribers
$7,503
Cost per Claim
100
Beneficiaries
20,534
30-Day Fills
$138K
Avg Cost/Provider
18
Avg Claims/Provider
About Ixekizumab
Ixekizumab (sold as Taltz Autoinjector) was prescribed 19,972 times by 1,087 Medicare Part D providers in 2023, costing the program $149.8M. At $7,503 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
| 113 | Rimegepant Sulfate (Nurtec Odt) | $155.0M | 106,692 |
| 114 | Teriparatide (Forteo) | $153.9M | 38,259 |
| 115 | Ixekizumab (Taltz Autoinjector) | $149.8M | 19,972 |
| 116 | Sofosbuvir/Velpatasvir (Epclusa) | $149.4M | 6,544 |
| 117 | Dolutegravir/Rilpivirine (Juluca) | $148.9M | 41,081 |
| 118 | Lisinopril (Lisinopril) | $145.8M | 15,744,768 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology